SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in […]
BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce that its management team will be attending and presenting at key scientific and investor conferences in April to June 2024. Read more…
Each year, In Vivo spotlights the next wave of entrepreneurs and innovators making a difference in the biopharma, medtech and health technology sectors. The 30 Rising Leaders have been recognised for their achievements, talent, creativity and leadership and this year include four of Optimum’s fantastic clients. Firstly, Anthony DeBoer, VP of Business Development at Synaffix, […]
More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]
It’s nearly the end of 2022! It was an exciting year for Optimum’s clients which demonstrated the resilience and creativity that has made the life sciences industry so successful. We have outlined below a small fraction of the activity that has kept us busy this year: Deal, deals, deals As usual, 2022 was a year […]
